Xiaflex 0.9 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FFBQ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,189
Award facts
- Contract value 100% obligated
- $25,189.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $25,189.38 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xiaflex 0.9 mg vials. The delivery order, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for the Department of Defense.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the federal military medical supply chain, with its PPV-G GEN V contract—valued at $499,999,999 with a ceiling through December 31, 2036—authorizing the DLA to issue firm fixed-price delivery orders for a comprehensive range of branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables to support Department of Defense healthcare facilities worldwide. The contractor's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the military healthcare system, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FFBQ8?
SPE2DR26FFBQ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FFBQ8 worth?
The government has obligated $25,189 on SPE2DR26FFBQ8.
Is contract SPE2DR26FFBQ8 an order under another contract?
Yes. SPE2DR26FFBQ8 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBQ8 competed?
The extent of competition for SPE2DR26FFBQ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award